{
    "organizations": [],
    "uuid": "9d536fa58a971645ba2eb13ccdd4fcfc71265ee9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-therapeutic-solutions-to-initiate/brief-therapeutic-solutions-to-initiate-clinical-trial-of-cancer-immunotherapy-adjuvant-nanostilbene-idUSASC0A2BH",
    "ord_in_thread": 0,
    "title": "BRIEF-Therapeutic Solutions To Initiate Clinical Trial Of Cancer Immunotherapy Adjuvant Nanostilbene",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Therapeutic Solutions International Inc :\n* THERAPEUTIC SOLUTIONS INTERNATIONAL, INC., TO INITIATE CLINICAL TRIAL OF PATENTED CANCER IMMUNOTHERAPY ADJUVANT NANOSTILBENE Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T21:29:00.000+03:00",
    "crawled": "2018-05-16T19:17:01.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "therapeutic",
        "solution",
        "international",
        "inc",
        "therapeutic",
        "solution",
        "international",
        "initiate",
        "clinical",
        "trial",
        "patented",
        "cancer",
        "immunotherapy",
        "adjuvant",
        "nanostilbene",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}